嬰兒 血管 瘤

1. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94. doi: 10.1016/S0140-6736(16)00645-0. [PubMed] [CrossRef] [Google Scholar]

2. Harbi S, Wang R, Gregory M, et al. Infantile hemangioma originates from a dysregulated but not fully transformed multipotent stem cell. Sci Rep. 2016;6:35811. doi: 10.1038/srep35811. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Ji Y, Wang Q, Chen S, et al. Oral atenolol therapy for proliferating infantile hemangioma:a prospective study. Medicine (Baltimore) 2016;95(24):e3908. doi: 10.1097/MD.0000000000003908. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Haggstrom AN, Garzon MC, Baselga E, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010;126(2):e418–e426. doi: 10.1542/peds.2009-3166. [PubMed] [CrossRef] [Google Scholar]

6. Winter PR, Itinteang T, Leadbitter P, et al. PHACE syndrome-clinical features, aetiology and management. Acta Paediatr. 2016;105(2):145–153. doi: 10.1111/apa.2016.105.issue-2. [PubMed] [CrossRef] [Google Scholar]

7. Hoornweg MJ, Smeulders MJ, Ubbink DT, et al. The prevalence and risk factors of infantile haemangiomas:a case-control study in the Dutch population. Paediatr Perinat Epidemiol. 2012;26(2):156–162. doi: 10.1111/ppe.2012.26.issue-2. [PubMed] [CrossRef] [Google Scholar]

8. Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447–1456. doi: 10.1542/peds.2009-0082. [PubMed] [CrossRef] [Google Scholar]

9. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas:an update on pathogenesis and therapy. Pediatrics. 2013;131(1):99–108. doi: 10.1542/peds.2012-1128. [PubMed] [CrossRef] [Google Scholar]

10. Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132(3):307–311. doi: 10.1001/archderm.1996.03890270083012. [PubMed] [CrossRef] [Google Scholar]

11. Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome:consensus-derived diagnosis and care recommendations. J Pediatr. 2016;178:24–33. doi: 10.1016/j.jpeds.2016.07.054. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Hess CP, Fullerton HJ, Metry DW, et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. AJNR Am J Neuroradiol. 2010;31(10):1980–1986. doi: 10.3174/ajnr.A2206. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136(4):e1060–e1104. doi: 10.1542/peds.2015-2485. [PubMed] [CrossRef] [Google Scholar]

15. Dai Y, Hou F, Buckmiller L, et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Arch Otolaryngol Head Neck Surg. 2012;138(2):177–182. doi: 10.1001/archoto.2011.1096. [PubMed] [CrossRef] [Google Scholar]

16. Kleinman ME, Blei F, Gurtner GC. Circulating endothelial progenitor cells and vascular anomalies. Lymphat Res Biol. 2005;3(4):234–239. doi: 10.1089/lrb.2005.3.234. [PubMed] [CrossRef] [Google Scholar]

17. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children:a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412–422. doi: 10.1097/00006534-198203000-00002. [PubMed] [CrossRef] [Google Scholar]

18. Kim ME, Cancel M, Metry D, et al. Evaluation of maternal history of miscarriage, infertility, and in vitro fertilization as associated factors in PHACE. Br J Dermatol. 2017;177(4):e90–e91. doi: 10.1111/bjd.15341. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Schilter KF, Steiner JE, Demos W, et al. RNF213 variants in a child with PHACE syndrome and moyamoya vasculopathy. Am J Med Genet A. 2017;173(9):2557–2561. doi: 10.1002/ajmg.a.v173.9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Cecchi AC, Guo D, Ren Z, et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Stroke. 2014;45(11):3200–3207. doi: 10.1161/STROKEAHA.114.006244. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Sullivan CT, Christian SL, Shieh JT, et al. X chromosome-inactivation patterns in 31 individuals with PHACE syndrome. Mol Syndromol. 2013;4(3):114–118. [PMC free article] [PubMed] [Google Scholar]

22. Colonna V, Resta L, Napoli A, et al. Placental hypoxia and neonatal haemangioma:clinical and histological observations. Br J Dermatol. 2010;162(1):208–209. doi: 10.1111/bjd.2009.162.issue-1. [PubMed] [CrossRef] [Google Scholar]

23. Nabatian AS, Milgraum SS, Hess CP, et al. PHACE without face? Infantile hemangiomas of the upper body region with minimal or absent facial hemangiomas and associated structural malformations. Pediatr Dermatol. 2011;28(3):235–241. doi: 10.1111/pde.2011.28.issue-3. [PubMed] [CrossRef] [Google Scholar]

24. Brandon K, Burrows P, Hess C, et al. Arteriovenous malformation:a rare manifestation of PHACE syndrome. Pediatr Dermatol. 2011;28(2):180–184. doi: 10.1111/pde.2011.28.issue-2. [PubMed] [CrossRef] [Google Scholar]

25. Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas:new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698–703. doi: 10.1542/peds.2005-1092. [PubMed] [CrossRef] [Google Scholar]

26. Ji Y, Chen S, Xiang B, et al. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas:a prospective study. Sci Rep. 2017;7(1):1503. doi: 10.1038/s41598-017-01321-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas:recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855–865. doi: 10.1007/s00431-015-2570-0. [PubMed] [CrossRef] [Google Scholar]

28. Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015;174(12):1579–1584. doi: 10.1007/s00431-015-2572-y. [PubMed] [CrossRef] [Google Scholar]

29. Winter PR, Itinteang T, Leadbitter P, et al. PHACE(S) syndrome with absent intracranial internal carotid artery and anomalous circle of willis. J Craniofac Surg. 2015;26(4):e315–e317. doi: 10.1097/SCS.0000000000001701. [PubMed] [CrossRef] [Google Scholar]

30. Vivas-Colmenares GV, Fernandez-Pineda I, Lopez-Gutierrez JC, et al. Analysis of the therapeutic evolution in the management of airway infantile hemangioma. World J Clin Pediatr. 2016;5(1):95–101. doi: 10.5409/wjcp.v5.i1.95. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Durr ML, Meyer AK, Huoh KC, et al. Airway hemangiomas in PHACE syndrome. Laryngoscope. 2012;122(10):2323–2329. doi: 10.1002/lary.v122.10. [PubMed] [CrossRef] [Google Scholar]

32. Ji Y, Chen S, Xu C, et al. The use of propranolol in the treatment of infantile haemangiomas:an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24–32. doi: 10.1111/bjd.2015.172.issue-1. [PubMed] [CrossRef] [Google Scholar]

33. Metry D, Frieden IJ, Hess C, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies:collective experience in 32 infants. Pediatr Dermatol. 2013;30(1):71–89. doi: 10.1111/pde.2013.30.issue-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma:report of a consensus conference. Pediatrics. 2013;131(1):128–140. doi: 10.1542/peds.2012-1691. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Webb AJ, Fischer U, Rothwell PM. Effects of β-blocker selectivity on blood pressure variability and stroke:a systematic review. Neurology. 2011;77(8):731–737. doi: 10.1212/WNL.0b013e31822b007a. [PubMed] [CrossRef] [Google Scholar]

36. Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome:a systematic review of the literature. Stroke. 2012;43(6):1672–1674. doi: 10.1161/STROKEAHA.112.650952. [PubMed] [CrossRef] [Google Scholar]

37. Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016;138(3):pii:e20160355. doi: 10.1542/peds.2016-0355. [PubMed] [CrossRef] [Google Scholar]

38. Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol. 2011;164(4):886–888. doi: 10.1111/bjd.2011.164.issue-4. [PubMed] [CrossRef] [Google Scholar]

39. Fontana E, Causin F, De Corti F, et al. Phace syndrome:is timolol gel a chance for treatment? J Eur Acad Dermatol Venereol. 2017;31(7):e345–e346. doi: 10.1111/jdv.2017.31.issue-7. [PubMed] [CrossRef] [Google Scholar]

40. Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas:cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222–224. doi: 10.1111/bjd.2012.168.issue-1. [PubMed] [CrossRef] [Google Scholar]

42. Kim KH, Choi TH, Choi Y, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma:a randomized clinical trial. JAMA Dermatol. 2017;153(6):529–536. doi: 10.1001/jamadermatol.2017.0250. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Janmohamed SR, Madern GC, Nieuwenhuis K, et al. Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy:still an alternative besides propranolol. Pediatr Surg Int. 2012;28(4):393–398. doi: 10.1007/s00383-011-3037-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies:a systematic review. Acta Derm Venereol. 2016;96(4):448–452. doi: 10.2340/00015555-2300. [PubMed] [CrossRef] [Google Scholar]

47. Phillips JD, Zhang H, Wei T, et al. Expression of β-adrenergic receptor subtypes in proliferative, involuted, and propranolol-responsive infantile hemangiomas. JAMA Facial Plast Surg. 2017;19(2):102–107. doi: 10.1001/jamafacial.2016.1188. [PubMed] [CrossRef] [Google Scholar]

48. Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma:a multicenter retrospective study. Int J Cancer. 2017;141(4):848–855. doi: 10.1002/ijc.v141.4. [PubMed] [CrossRef] [Google Scholar]

49. Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol. 2013;30(6):e194–e197. doi: 10.1111/pde.2013.30.issue-6. [PubMed] [CrossRef] [Google Scholar]